CA2359110A1 - Combination of hepatitis b vaccine with antiviral agents - Google Patents

Combination of hepatitis b vaccine with antiviral agents Download PDF

Info

Publication number
CA2359110A1
CA2359110A1 CA002359110A CA2359110A CA2359110A1 CA 2359110 A1 CA2359110 A1 CA 2359110A1 CA 002359110 A CA002359110 A CA 002359110A CA 2359110 A CA2359110 A CA 2359110A CA 2359110 A1 CA2359110 A1 CA 2359110A1
Authority
CA
Canada
Prior art keywords
hepatitis
pharmaceutical pack
vaccine
antiviral agent
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002359110A
Other languages
English (en)
French (fr)
Inventor
Ronald James Boon
Pierre G. Vandepapeliere
Gillian Frances Atkinson
Martine Anne Cecile Wettendorff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2359110A1 publication Critical patent/CA2359110A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
CA002359110A 1999-01-12 1999-12-21 Combination of hepatitis b vaccine with antiviral agents Abandoned CA2359110A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9900630 1999-01-12
GB9900630.6 1999-01-12
PCT/EP1999/010295 WO2000041463A2 (en) 1999-01-12 1999-12-21 Combination of hepatitis b vaccine with antiviral agents

Publications (1)

Publication Number Publication Date
CA2359110A1 true CA2359110A1 (en) 2000-07-20

Family

ID=10845878

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002359110A Abandoned CA2359110A1 (en) 1999-01-12 1999-12-21 Combination of hepatitis b vaccine with antiviral agents

Country Status (19)

Country Link
EP (1) EP1140163A2 (ko)
JP (1) JP2002534438A (ko)
KR (1) KR20010090011A (ko)
CN (1) CN1391482A (ko)
AR (1) AR022250A1 (ko)
AU (1) AU760574B2 (ko)
BR (1) BR9916893A (ko)
CA (1) CA2359110A1 (ko)
CO (1) CO5241355A1 (ko)
CZ (1) CZ20012544A3 (ko)
HK (1) HK1041434A1 (ko)
HU (1) HUP0105070A2 (ko)
IL (1) IL144186A0 (ko)
NO (1) NO20013337L (ko)
NZ (1) NZ512890A (ko)
PL (1) PL349347A1 (ko)
TR (1) TR200102024T2 (ko)
WO (1) WO2000041463A2 (ko)
ZA (1) ZA200105690B (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2628744T3 (es) 1998-05-22 2017-08-03 Ottawa Hospital Research Institute Métodos y productos para inducir inmunidad en mucosas
ATE420112T1 (de) 1998-07-31 2009-01-15 Int Inst Cancer Immunology Inc Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1
EP1371664B1 (en) 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti modified peptide
WO2003028757A1 (fr) * 2001-09-28 2003-04-10 Haruo Sugiyama Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes
US20050002951A1 (en) * 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
MY131488A (en) * 2002-04-08 2007-08-30 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
CN101948835A (zh) 2002-10-29 2011-01-19 科勒制药集团股份有限公司 Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
JP2006512927A (ja) 2002-12-11 2006-04-20 コーリー ファーマシューティカル グループ，インコーポレイテッド ５’ｃｐｇ核酸およびその使用方法
CN100443117C (zh) * 2003-05-13 2008-12-17 深圳康泰生物制品股份有限公司 一种治疗性乙型肝炎的疫苗制剂、其制备方法及其用途
US8541167B2 (en) 2004-06-03 2013-09-24 Saint Louis University Methods and compositions for vaccination
AR065504A1 (es) * 2007-02-28 2009-06-10 Ct Ingenieria Genetica Biotech Terapia combinada para el tratamiento de la hepatitis b cronica. uso.
US20220088188A1 (en) * 2018-12-24 2022-03-24 Grand Theravac Life Science (Nanjing) Co., Ltd. Pharmaceutical preparation for treating hepatitis b, preparation method therefor and use thereof
WO2022215737A1 (ja) * 2021-04-07 2022-10-13 デンカ株式会社 アジュバント活性増強剤及びアジュバント組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE159031T1 (de) * 1989-07-25 1997-10-15 Smithkline Biolog Antigene sowie verfahren zu deren herstellung
HUP0101047A3 (en) * 1998-03-09 2004-10-28 Smithkline Beecham Biolog Combined vaccine compositions

Also Published As

Publication number Publication date
HUP0105070A2 (hu) 2002-04-29
NO20013337L (no) 2001-08-17
PL349347A1 (en) 2002-07-15
BR9916893A (pt) 2001-11-20
HK1041434A1 (zh) 2002-07-12
AU2100900A (en) 2000-08-01
CO5241355A1 (es) 2003-01-31
EP1140163A2 (en) 2001-10-10
IL144186A0 (en) 2002-05-23
CZ20012544A3 (cs) 2002-01-16
ZA200105690B (en) 2002-09-25
TR200102024T2 (tr) 2001-12-21
WO2000041463A3 (en) 2000-11-09
NO20013337D0 (no) 2001-07-05
WO2000041463A2 (en) 2000-07-20
KR20010090011A (ko) 2001-10-17
AU760574B2 (en) 2003-05-15
AR022250A1 (es) 2002-09-04
CN1391482A (zh) 2003-01-15
JP2002534438A (ja) 2002-10-15
NZ512890A (en) 2003-09-26

Similar Documents

Publication Publication Date Title
JP3530526B2 (ja) ＨＳＶ糖蛋白質ｇＤおよび３脱アシル化モノホスホリルリピッドＡからなる単純ヘルペスワクチン
AU760574B2 (en) Novel treatment
Ocama et al. Hepatitis B virus infection: current status
JP3470719B2 (ja) ３−ｏ−脱アシル化モノホスホリル脂質ａ含有の肝炎ワクチン
JP4126067B2 (ja) アジュバント組成物
AP408A (en) Vaccine composition containing adjuvants.
JP4510283B2 (ja) 併合ワクチン組成物
Dupont et al. A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine
US9878035B2 (en) Hepatitis B vaccine
KR19980702480A (ko) Ｂ형 간염 백신
JPH08508722A (ja) ３−ｏ脱アシル化モノホスホリルリピドａ含有ワクチン組成物
WO2015196935A1 (zh) 含有CpG寡核苷酸的药物组合物
CN101309931B (zh) 包含截短的hbc核心蛋白和基于皂苷的佐剂的疫苗
JP5138843B2 (ja) 新規組成物
MXPA01007112A (en) Novel treatment
Huang et al. New advances in hepatitis B vaccination for adults
Lu et al. Induction of antibodies to the PreS region of surface antigens of woodchuck hepatitis virus (WHV) in chronic carrier woodchucks by immunizations with WHV surface antigens
KR20210151047A (ko) B형 간염 치료를 위한 면역원성 조성물
JP2022516041A (ja) Ｂ型肝炎を治療するための薬物製剤、その製造方法及び用途
CN109219449B (zh) 包含乙型肝炎病毒的表面抗原和核衣壳抗原的药用组合物
US7144703B2 (en) Composition
Sangar et al. NINE-VALENT HUMAN PAPILLOMAVIRUS VACCINE (V503/GARDASIL9®): A REVIEW
Vanlandschoot et al. A temperature-dependent inhibitory activity of serum on the capacity of Saccharomyces cerevisiae-derived hepatitis B surface antigen to bind to monocytes
Yoon Clinical Experience of HBV DNA Vaccine in Korean Patients with Chronic HBV Infection
BRPI0017420B1 (pt) Composição de vacina, hpv 16 l1 e hpv 18 l1 vpl

Legal Events

Date Code Title Description
FZDE Discontinued